TY - JOUR
T1 - Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer
AU - Nguyen, Paul L.
AU - Jarolim, Petr
AU - Basaria, Shehzad
AU - Zuflacht, Jonah P.
AU - Milian, Jessica
AU - Kadivar, Samoneh
AU - Graham, Powell L.
AU - Hyatt, Andrew
AU - Kantoff, Philip W.
AU - Beckman, Joshua A.
N1 - Publisher Copyright:
© 2015 The Authors.
PY - 2015
Y1 - 2015
N2 - Background-Androgen deprivation therapy (ADT) is a standard treatment for patients with aggressive prostate cancer. AlthoughADT improves survival, it increases the risk of diabetes. Emerging evidence suggests that ADT increases adverse cardiovascularevents as early as 3 months after initiation in patients with cardiovascular disease, but the mechanism is unknown. Wehypothesized that ADT may impair endothelium-dependent vasodilation due to increases in lipids and insulin resistance and mayprovide a link for heightened cardiovascular risk in this population.Methods and Results-We prospectively evaluated conduit artery endothelium-dependent and -independent vasodilation, lipids,and insulin resistance in 16 consecutively treated men (mean age 66±7 years; 25% with diabetes) with prostate cancer before andafter 3 months of ADT. High-resolution B-mode ultrasound was used to assess flow-mediated (endothelium-dependent) andnitroglycerine-mediated (endothelium-independent) brachial artery vasodilation. ADT significantly increased insulin resistance, totalcholesterol, HDL, and LDL. Endothelium-dependent vasodilation was greater at 3 months than at baseline (10.8% [interquartilerange: 7.7% to 14.6%] versus 8.9% [interquartile range: 4.0% to 12.6%], respectively; P=0.046, allometric P=0.037). Nitroglycerinemediatedvasodilation did not change from baseline (P>0.2). The subset of participants on ADT for 6 months returned forreevaluation at 1 year. In this group, endothelium-dependent vasodilation increased from baseline to 3 months and returned tobaseline 6 months after ADT withdrawal (9.4% [interquartile range: 6.9% to 10.9%], 11.6% [interquartile range: 7.9% to 15.2%], and9.0% [interquartile range: 5.1% to 12.5%], respectively; P=0.05).Conclusions-In contrast to our expectation, ADT improved endothelium-dependent vasodilation and its cessation returnedendothelium-dependent vasodilation to baseline. Determining the mechanism of this change requires further investigation.
AB - Background-Androgen deprivation therapy (ADT) is a standard treatment for patients with aggressive prostate cancer. AlthoughADT improves survival, it increases the risk of diabetes. Emerging evidence suggests that ADT increases adverse cardiovascularevents as early as 3 months after initiation in patients with cardiovascular disease, but the mechanism is unknown. Wehypothesized that ADT may impair endothelium-dependent vasodilation due to increases in lipids and insulin resistance and mayprovide a link for heightened cardiovascular risk in this population.Methods and Results-We prospectively evaluated conduit artery endothelium-dependent and -independent vasodilation, lipids,and insulin resistance in 16 consecutively treated men (mean age 66±7 years; 25% with diabetes) with prostate cancer before andafter 3 months of ADT. High-resolution B-mode ultrasound was used to assess flow-mediated (endothelium-dependent) andnitroglycerine-mediated (endothelium-independent) brachial artery vasodilation. ADT significantly increased insulin resistance, totalcholesterol, HDL, and LDL. Endothelium-dependent vasodilation was greater at 3 months than at baseline (10.8% [interquartilerange: 7.7% to 14.6%] versus 8.9% [interquartile range: 4.0% to 12.6%], respectively; P=0.046, allometric P=0.037). Nitroglycerinemediatedvasodilation did not change from baseline (P>0.2). The subset of participants on ADT for 6 months returned forreevaluation at 1 year. In this group, endothelium-dependent vasodilation increased from baseline to 3 months and returned tobaseline 6 months after ADT withdrawal (9.4% [interquartile range: 6.9% to 10.9%], 11.6% [interquartile range: 7.9% to 15.2%], and9.0% [interquartile range: 5.1% to 12.5%], respectively; P=0.05).Conclusions-In contrast to our expectation, ADT improved endothelium-dependent vasodilation and its cessation returnedendothelium-dependent vasodilation to baseline. Determining the mechanism of this change requires further investigation.
KW - Androgen deprivation therapy
KW - Endothelial function
KW - Inflammation
KW - Insulin resistance
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85012278961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012278961&partnerID=8YFLogxK
U2 - 10.1161/JAHA.115.001914
DO - 10.1161/JAHA.115.001914
M3 - Article
C2 - 25896892
AN - SCOPUS:85012278961
SN - 2047-9980
VL - 4
SP - e001914
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 4
ER -